Monte Rosa Therapeutics, Inc. (GLUE) Stock Forecast
GLUE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 10 analysts
- Price target
- $26.88 average of analyst targets
- Upside to target
- +175.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.10
- 52-week range
- $9.35 – $25.31
GLUE analyst ratings
10 analystsNumber of analysts at each rating.
GLUE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GLUE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.56 | $0.10 | −$0.33 | +39.0% | 9 |
| Current fiscal year (2026) | −$1.42 | −$2.02 | −$0.41 | −$0.46 | −208.0% | 9 |
| Next fiscal year (2027) | −$1.85 | −$3.15 | $0.24 | −$1.42 | −30.3% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GLUE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $33.9M | $0 | $67.0M | +165.4% | 9 |
| Current fiscal year (2026) | $68.3M | $13.2M | $190.8M | −44.7% | 9 |
| Next fiscal year (2027) | $64.6M | $0 | $286.3M | −5.5% | 9 |
GLUE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GLUE revenue: reported and forecast
GLUE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.35 | −$0.23 | −$0.22 | −$0.20 | −47.0% | 2 up · 0 down |
| Current fiscal year (2026) | −$1.59 | −$1.57 | −$1.45 | −$1.43 | −$1.42 | −11.0% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.81 | −$1.88 | −$1.87 | −$1.95 | −$1.85 | +1.8% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GLUE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GLUE beat in 7 of 12.
What analysts expect from GLUE
10 analysts cover Monte Rosa Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $26.88, 175.9% above the latest close of $9.74. Analysts expect earnings of −$1.42 per share for 2026, −208.0% from a year earlier. For 2027 the average estimate is −$1.85 per share on revenue of $64.6 million. Monte Rosa Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: GLUE income statement, GLUE key metrics, GLUE chart. See the GLUE stock overview for the latest quote and news.
GLUE forecast FAQ
What is Monte Rosa Therapeutics's price target?
The average analyst price target for Monte Rosa Therapeutics is $26.88, 175.9% above the latest close of $9.74.
Is Monte Rosa Therapeutics a buy, hold or sell?
Of 10 analysts covering Monte Rosa Therapeutics, 8 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Monte Rosa Therapeutics's EPS forecast?
Analysts forecast −$1.42 per share for 2026 (range −$2.02 to −$0.41); for 2027 the estimate is −$1.85.
What is Monte Rosa Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $68.3 million, growth of −44.7%; for 2027 it is $64.6 million.
When does Monte Rosa Therapeutics report earnings?
Monte Rosa Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.10.
Does Monte Rosa Therapeutics usually beat earnings estimates?
Monte Rosa Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.